Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076688 | 0.86 | CA3 (0.46) | ESR1ESR2CA3CA6CA5A | |
| SCHEMBL21259084 | 0.80 | ESR2 (0.39) | ESR1ESR2MAPTTDP1L3MBTL1 | |
| SCHEMBL1020440 | 0.79 | PSEN1 (0.40) | ESR1ESR2CA3CA6CA5A | |
| SCHEMBL29618975 | 0.79 | PSEN1 (0.40) | ESR1ESR2CA3CA6CA5A | |
| SCHEMBL6903574 | 0.77 | ESR2 (0.40) | ESR1ESR2CYP19A1MAPTTDP1 | |
| SCHEMBL1616373 | 0.76 | HIF1A (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL10653163 | 0.76 | MEN1 (0.44) | ESR1ESR2MAPTTDP1L3MBTL1 | |
| SCHEMBL5642630 | 0.76 | KCNH2 (0.39) | MPOSLC6A4MAPTTDP1L3MBTL1 | |
| SCHEMBL3067521 | 0.76 | AMY1A (0.53) | MAPTTDP1MEN1ALDH1A1LMNA | |
| SCHEMBL22904292 | 0.76 | MAOA (0.41) | MPOSLC6A4FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171864-A1 | Fluorinated aromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1431279-A2 | Fluoride containing aromatic compounds | Bayer Chemicals AG (DE) | 2004-06-23 | — | — | EP | claimed |
| CN-117586277-A | Macrocyclic triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011046771-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-20040171864-A1 | Fluorinated aromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1431279-A2 | Fluoride containing aromatic compounds | Bayer Chemicals AG (DE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ESR1 1697/4885ESR2 1370/4885CA3 3440/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ESR1 1697/4885ESR2 1370/4885CA3 3440/4885 |
| US-20040171864-A1 | Fluorinated aromatics | AFF1, AFF2, AFF4 | ESR1 1239/4885ESR2 2493/4885CA3 2890/4885 |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | ESR1 3644/4885ESR2 2183/4885CA3 2300/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | ESR1 3594/4885ESR2 1914/4885CA3 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.